XML 26 R19.htm IDEA: XBRL DOCUMENT
v3.26.1

NET LOSS PER SHARE | 3 Months Ended
--- | ---
Mar. 31, 2026
Earnings Per Share [Abstract] |
NET LOSS PER SHARE | 11. NET LOSS PER SHARE Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock of the Company outstanding during the period. Diluted net loss per share is computed by giving effect to all common equivalent shares of the Company, including outstanding stock options, RSUs, and warrants to the extent dilutive. Basic and diluted net loss per share was the same for each period presented as the inclusion of all common equivalent shares of the Company outstanding would have been anti-dilutive. The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock:
|  | Three Months Ended March 31, |
|  | 2026 |  |  | 2025 |
Numerator: |  |  |  |  |  |
Net Loss |  | $ | (8,623 | ) |  | $ | (9,418 | )
Numerator for Basic and Dilutive EPS – Loss available to common stockholders |  | $ | (8,623 | ) |  | $ | (9,418 | )
Denominator: |  |  |  |  |  |
Common Stock |  |  | 97,695,133 |  |  |  | 75,697,199 |
Denominator for Basic and Dilutive EPS - Weighted-average common stock |  |  | 97,695,133 |  |  |  | 75,697,199 |
Basic and dilutive net loss per share |  | $ | (0.09 | ) |  | $ | (0.12 | )
Since the Company was in a net loss position for all periods presented, net loss per share attributable to Class A and Class B common stockholders was the same on a basic and diluted basis, as the inclusion of all common equivalent shares outstanding would have been anti-dilutive. Anti-dilutive common equivalent shares were as follows:
|  | Three Months Ended March 31, |
|  | 2026 |  |  | 2025 |
Outstanding options to purchase common stock |  |  | 15,336,803 |  |  |  | 17,954,246 |
Outstanding RSUs |  |  | 5,707,929 |  |  |  | 2,441,983 |
Warrants issued in connection with February 2025 Offering |  |  | 4,257,419 |  |  |  | 4,511,178 |
Warrants issued in connection with Loan Agreement |  |  | 562,500 |  |  |  | — |
Total anti-dilutive common equivalent shares |  |  | 25,864,651 |  |  |  | 24,907,407 |
The Loan Agreement also provides for Additional Warrants to purchase up to an aggregate of 520,835 shares of Class A common stock at an exercise price of $1.20 per share, contingent on and exercisable only upon the funding of future term loan tranche s under the Loan Agreement. As no additional term loan tranches had been drawn as of March 31, 2026, no shares were issuable under the Additional Warrants as of March 31, 2026, and such Additional Warrants were excluded from the table above.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration